These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28833211)

  • 41. Effects of negative air ions (NAIs) on Leishmania major: A novel tool for treatment of zoonotic cutaneous leishmaniasis (ZCL).
    Badirzadeh A; Najm M; Hemphill A; Alipour M; Hasanpour H; Masoori L; Karimi P
    PLoS One; 2022; 17(9):e0274124. PubMed ID: 36074764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Leishmania major: targeting IL-4 in successful immunomodulation of murine infection.
    Wakil AE; Wang ZE; Locksley RM
    Exp Parasitol; 1996 Nov; 84(2):214-22. PubMed ID: 8932771
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Codelivery of DNA vaccination encoding LeIF gene and IL-12 increases protection against Leishmania major infection in BALB/c mice.
    Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A
    Parasite Immunol; 2016 Apr; 38(4):228-35. PubMed ID: 26868280
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction of Macrophage Antigen 1 and CD40 Ligand Leads to IL-12 Production and Resistance in CD40-Deficient Mice Infected with Leishmania major.
    Okwor I; Jia P; Uzonna JE
    J Immunol; 2015 Oct; 195(7):3218-26. PubMed ID: 26304989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice.
    Kremer IB; Gould MP; Cooper KD; Heinzel FP
    Infect Immun; 2001 Feb; 69(2):673-80. PubMed ID: 11159954
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.
    Pirdel L; Farajnia S
    Scand J Immunol; 2017 Jul; 86(1):15-22. PubMed ID: 28426153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
    Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
    J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors influencing Leishmania major infection in IL-4-deficient BALB/c mice.
    Kropf P; Herath S; Weber V; Modolell M; Müller I
    Parasite Immunol; 2003; 25(8-9):439-47. PubMed ID: 14651591
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody.
    Nabors GS; Farrell JP
    Am J Trop Med Hyg; 1995 Jul; 53(1):55-60. PubMed ID: 7625533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
    Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
    J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pretreatment of macrophages with the combination of IFN-gamma and IL-12 induces resistance to Leishmania major at the early phase of infection.
    Ota H; Takashima Y; Matsumoto Y; Hayashi Y; Matsumoto Y
    J Vet Med Sci; 2008 Jun; 70(6):589-93. PubMed ID: 18628599
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A lentiviral vaccine expressing KMP11-HASPB fusion protein increases immune response to Leishmania major in BALB/C.
    Mortazavidehkordi N; Fallah A; Abdollahi A; Kia V; Khanahmad H; Najafabadi ZG; Hashemi N; Estiri B; Roudbari Z; Najafi A; Farjadfar A; Hejazi SH
    Parasitol Res; 2018 Jul; 117(7):2265-2273. PubMed ID: 29845415
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Leishmania major: differential resistance to infection in C57BL/6 (high interferon-alpha/beta) and congenic B6.C-H-28c (low interferon-alpha/beta) mice.
    Shankar AH; Morin P; Titus RG
    Exp Parasitol; 1996 Nov; 84(2):136-43. PubMed ID: 8932763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Leishmania major: effect of infectious dose on T cell subset development in BALB/c mice.
    Doherty TM; Coffman RL
    Exp Parasitol; 1996 Nov; 84(2):124-35. PubMed ID: 8932762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
    Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
    Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant.
    Bayih AG; Daifalla NS; Gedamu L
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3391. PubMed ID: 25500571
    [TBL] [Abstract][Full Text] [Related]  

  • 57. c-Rel promotes type 1 and type 17 immune responses during Leishmania major infection.
    Reinhard K; Huber M; Wostl C; Hellhund A; Toboldt A; Abass E; Casper B; Joeris T; Herr C; Bals R; Steinhoff U; Lohoff M; Visekruna A
    Eur J Immunol; 2011 May; 41(5):1388-98. PubMed ID: 21469108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antitumor Effect of IP-10 by Using Two Different Approaches: Live Delivery System and Gene Therapy.
    Taslimi Y; Zahedifard F; Habibzadeh S; Taheri T; Abbaspour H; Sadeghipour A; Mohit E; Rafati S
    J Breast Cancer; 2016 Mar; 19(1):34-44. PubMed ID: 27066094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protective immunity against Leishmania major induced by Leishmania tropica infection of BALB/c mice.
    Mahmoudzadeh-Niknam H; Kiaei SS; Iravani D
    Exp Parasitol; 2011 Feb; 127(2):448-53. PubMed ID: 21035446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.